MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Tardive Cervical Dystonia: Treatment with Botulinum: Treatment with Botulinum Toxin Guided by Electromyography

LFV. Vasconcellos, MS. Spitz, DN. Nassif, BRA. Andrade (Rio de Janeiro, Brazil)

Meeting: 2019 International Congress

Abstract Number: 1352

Keywords: Botulinum toxin: Clinical applications: dystonia, Dystonia: Treatment, Xeomin

Session Information

Date: Tuesday, September 24, 2019

Session Title: Dystonia

Session Time: 1:45pm-3:15pm

Location: Les Muses Terrace, Level 3

Objective: To describe the use of botulinum toxin in the treatment of tardive dystonia.

Background: Tardive dystonia (TD) was recognized as a complication of dopamine receptor blocking agents such as antipsychotic and anti-emetic drugs since 1960s. The risk of developing (TD) begins with the initiation of therapy, there being no safe period of exposure, with a wide range of development after exposure, ranging from days to decades.

Method: A 53-year-old man, diagnosed with paranoid schizophrenia at 17 years of age, has been treated with first and second generation neuroleptics for about 20 years. Started in 2010 a cervical and facial dystonia with pain that progressed to a disabling condition not responsive to the pharmacological approach (clonazepam and clozapine). The physical examination showed intense cervical dystonia with marked retrocollis and laterocollis to the right with sensory trick, and facial spasms.(vídeo) There was a marked functional recovery after the application of botulinum toxin type A (BT TX) guided by electromyography (EMG) in cervical muscles. The effect of BT TX had a duration of 4 months, requiring regular applications.

Results: Men tend to develop TD after shorter exposure and in a younger age when compared to women. Although BT TX is widely used in the treatment of dystonia and spasticity, there are few studies on its use in TD, but the effect seems to be similar to idiopathic dystonias, with de TD requiring larger doses . The patient in question achieved marked improvement after application of BT TX, with great improvement of mobility and resolution of pain, transiting of severe functional disability to oligosymptomatic state, with physical examination showing only discrete laterocollis. Although good results with BT TX are common, such expressive results are uncommon in the literature.

Conclusion: It is clear that further studies are needed to understand the range of responses to treatment presented by patients with TD. TX BT should be considered in this cases guided by EMG when possible to obtain better results. The understanding of the pathophysiology and the mechanisms involved in the pharmacological responses should bring advances in the treatment of TD in the future.

Fig  TX BT dystonia

To cite this abstract in AMA style:

LFV. Vasconcellos, MS. Spitz, DN. Nassif, BRA. Andrade. Tardive Cervical Dystonia: Treatment with Botulinum: Treatment with Botulinum Toxin Guided by Electromyography [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/tardive-cervical-dystonia-treatment-with-botulinum-treatment-with-botulinum-toxin-guided-by-electromyography/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/tardive-cervical-dystonia-treatment-with-botulinum-treatment-with-botulinum-toxin-guided-by-electromyography/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley